Cidofovir

別名：HPMPC, GS 0504

製品コード：S1516 純度：99.89%

Cidofovir suppresses virus replication by selective inhibition of viral DNA synthesis.

CAS No. 113852-37-2

サイズ	価格(税別)	在庫状況
25mg	JPY 22000	国内在庫あり
100mg	JPY 40500	国内在庫あり

代表番号: 045-509-1970\|電子メール：sales@selleck.co.jp よく尋ねられる質問

文献中Selleckの製品使用例（8）

カスタマーフィードバック2例

製品安全説明書

現在のバッチを見る：純度： 99.89%

99.89

Cidofovir関連製品

関連ターゲット	tRNA synthetase RdRp DNA synthesis helicase ribonucleotide reductase	もっと見る
関連製品	CX-5461 (Pidnarulex) SCR7 Favipiravir (T-705) RK-33 Carmofur Triapine (3-AP) B02 BMH-21 YK-4-279 Bergapten Tegafur (FT-207) Azaguanine-8 Halofuginone Adenine HCl Mizoribine Cyclocytidine HCl Thymidine APX-3330 Nedaplatin 6-Thio-dG Flupirtine maleate JH-RE-06 Pritelivir (BAY 57-1293) TK216 Amenamevir Madrasin Tubercidin BC-LI-0186 CRT0044876 PFM01 Adenine ML216	もっと見る
関連化合物ライブラリー	FDA-approved Drug Library Natural Product Library Apoptosis Compound Library DNA Damage/DNA Repair compound Library Cell Cycle compound library	もっと見る

シグナル伝達経路

DNA/RNA Synthesisシグナル伝達経路

DNA/RNA Synthesis阻害剤の選択性比較

Cell Data

Cell Lines	Assay Type	Incubation Time	活性情報
HEL cells	Function assay	3 days	Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days, EC50=0.41 μM
HEL cells	Function assay	3 days	Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days, EC50=0.41 μM
HFF	Proliferation assay	3 days	Antiproliferative activity against HFF after 3 days by coulter counter assay, EC50=1.9 μM
HeLaS3 cells	Function assay	3-5 days	Antiviral activity against Vaccinia virus IHD-J ATCC VR-156 infected in HeLaS3 cells after 3 to 5 days by plaque assay, EC50=18.74 μM
HSB2 cells	Function assay	7 days	Antiviral activity against Human herpesvirus 6 GS infected in human HSB2 cells assessed as decrease in viral DNA accumulation after 7 days, EC50=2.7 μM
HEL cells	Function assay		Compound was tested for anti-viral activity against HSV-1(KOS) in HEL cells, EC50=0.57 μM
MRC-5 cells	Function assay		Inhibitory activity against cytopathic effect of HSV-2(E 194) in MRC-5 cells, IC50=10 μM
NHDF cells	Function assay		Inhibitory activity against replication of HCMV in NHDF cells, IC50=0.5 μM
HFF cells	Function assay		Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction in cytopathogenicity, EC50=3.2 μM
HFF cells	Function assay		Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction in cytopathogenicity, EC50=7.1 μM
HFF cells	Function assay		Antiviral activity against vaccinia virus Copenhagen measured as cytopathogenicity in HFF cells, EC50=6.9 μM
bone marrow cells	Cytotoxicity assay		Cytotoxicity against human bone marrow cells assessed as inhibition of colony forming unit of granulocyte/macrophage, IC50=10 μM
HFF cells	Function assay		Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay, IC50=0.3 μM
MRC5 cells	Function assay		Antiviral activity against Human CMV Towne in MRC5 cells by PRA, IC50=0.3 μM
UC1B cells	Function assay		Antiviral activity against Murine polyomavirus MN/RDE Toronto in mouse UC1B cells assessed as reduction of virus-induced cytopathogenicity, EC50=13 μM
african green monkey Vero cells	Function assay		Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs, EC50=14.4 μM
HFF cells	Function assay		Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay, EC50=0.22 μM
HEL cells	Function assay		Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50=0.74 μM
HEL cells	Function assay		Antiviral activity against HCMV Davis infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection, EC50=0.5 μM
HEL cells	Function assay		Antiviral activity against HCMV AD169 infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection, EC50=0.3 μM
HEL cells	Function assay		Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity, IC50=0.045 μM
A549 cells	Function assay		Antiviral activity against Human adenovirus type 11p slobitski infected in A549 cells assessed as inhibition of DNA replication by QPCR assay, EC50=16.5 μM
HFF cells	Function assay		Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay, EC50=6.7 μM
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明	Cidofovir suppresses virus replication by selective inhibition of viral DNA synthesis.

In Vitro
In vitro	Cidofovir inhibits human cytomegalovirus (HCMV) infection in cultured cells. This compound is inhibitory to CMV plaque formation even when added to the cells at 48 hr post infection with IC50 of 0.9 μg/mL for Davis and 1.6 μg/mL for AD-169 strains,respectively. ^[1] It also inhibits herpes simplex virus infection. In addition, this chemical blocks cell fusion induced by HSV-1 in monkey kidney cells and blocks the expression of HSV-l-specific proteins and the synthesis of viral DNA. ^[3]

In Vivo
In Vivo	Cidofovir (5 mg/kg/day) subcutaneously for 5 days significantly reduces average virus infectivity titer in blood, spleen, lung and salivary gland in infected guinea pigs. This compound significantly reduces lymphocytosis and average tissue indexe of spleen in infected animals. ^[2]. It suppresses all manifestations (skin lesions, paralysis of the hind legs, and mortality) of hairless mice infected intracutaneously with HSV-1 or HSV-2. The most remarkable feature of this compound is that a single administration of the compound, even as late as 4 days after infection, conferees significant protection against HSV-1 or HSV-2 infection. ^[4] This chemical inhibits growth of the highly aggressive melanoma tumor arising from mouse melanoma B16 cells grafted subcutaneously in C57B16/J mice. ^[5]

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT04542252	Completed	Drug Drug Interaction	SymBio Pharmaceuticals	November 9 2020	Phase 1
NCT01610765	Withdrawn	Herpes Simplex Virus	University of Alabama at Birmingham	January 2016	Phase 1\|Phase 2
NCT01816646	Completed	Blood And Marrow Transplantation	M.D. Anderson Cancer Center\|Gilead Sciences	September 2013	Phase 1
NCT00780182	Completed	Healthy	Chimerix\|National Institutes of Health (NIH)	October 2008	Phase 1

参考
https://pubmed.ncbi.nlm.nih.gov/2854454/ https://pubmed.ncbi.nlm.nih.gov/2168690/ https://pubmed.ncbi.nlm.nih.gov/1332603/ https://pubmed.ncbi.nlm.nih.gov/2069375/ https://pubmed.ncbi.nlm.nih.gov/11069450/ + 展開

参考

https://pubmed.ncbi.nlm.nih.gov/2854454/
https://pubmed.ncbi.nlm.nih.gov/2168690/
https://pubmed.ncbi.nlm.nih.gov/1332603/

https://pubmed.ncbi.nlm.nih.gov/2069375/
https://pubmed.ncbi.nlm.nih.gov/11069450/

+ 展開

化学情報

分子量	279.19	化学式	C₈H₁₄N₃O₆P
CAS No.	113852-37-2	SDF	Download Cidofovir SDFをダウンロードする
Smiles	C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	１ケ月-20°Cin solvent

In vitro
Batch:

Water : 5 mg/mL

DMSO : Insoluble ( 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):